Characterization Of Antibody-Drug Conjugate Critical Quality Attributes

Antibody-drug conjugates (ADCs) merge the targeting precision of monoclonal antibodies with the potency of cytotoxic drugs, enabling high local drug concentrations while limiting off-target effects. Achieving consistent performance, however, depends on mastering complex design and characterization challenges—antibody specificity, linker stability, payload selection, and tight control of drug-to-antibody ratio (DAR). DAR, a critical quality attribute, directly influences efficacy, toxicity, and pharmacokinetics, making robust analytical strategies essential for managing inherent heterogeneity. Emerging formats like antibody-oligonucleotide conjugates (AOCs) and other next-generation constructs expand these challenges further by introducing diverse payload chemistries. Selecting appropriate separation and analytical techniques becomes critical to accurately characterize these molecules and ensure reliable development outcomes.

Gain insight into the strategies shaping effective conjugate analysis and development.